Weekly Digest - October 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2025
29 September 2025: Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase 3 trial in patients with high-risk early breast cancer following neoadjuvant therapy
- The Phase 3 DESTINY-Breast05 trial showed Enhertu delivered a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared with trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer patients with residual disease after neoadjuvant therapy
- This marks the second positive Phase 3 trial for Enhertu in early HER2-positive breast cancer, following DESTINY-Breast11, reinforcing its potential as a foundational treatment in the curative-intent setting
- Overall survival (OS) data were not mature at the interim analysis and will be evaluated in a future analysis
- Full results from DESTINY-Breast05 and DESTINY-Breast11 will be presented at ESMO 2025, and DESTINY-Breast05 data will be shared with global regulatory authorities
